e-learning
resources
Virtual 2021
08.09.2021
Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data
T. Maher (Los Angeles, United States of America), B. Langford (London, United Kingdom), A. Diamantopoulos (London, United Kingdom), K. Rohr (Ingelheim am Rhein, Germany), M. Baldwin (Ingelheim am Rhein, Germany), Y. Inoue (Osaka, Japan)
Source:
Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Session:
Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Session type:
Oral Presentation
Number:
4238
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Maher (Los Angeles, United States of America), B. Langford (London, United Kingdom), A. Diamantopoulos (London, United Kingdom), K. Rohr (Ingelheim am Rhein, Germany), M. Baldwin (Ingelheim am Rhein, Germany), Y. Inoue (Osaka, Japan). Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data. 4238
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
The prevalence of neoplastic transformation in idiopathic pulmonary fibrosis (IPF) lungs. A report from a transplanted IPF population
Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis
Year: 2011
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF?
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Does emphysema coexistence with IPF change prognosis?
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept